ライフサイエンスコーパス: BMT

1 BMT experiments revealed that BM-derived macrophages exp

2 BMT-derived microglia engraftment was significantly redu

3 BMT-exposed neonates had higher mean gestational age and

4 BMT-recipient mice receiving donor T cells with enhanced

5 study consisting of 2 cohorts, totaling 2888 BMT recipients with acute myeloid leukemia, acute lympho

6 luble and plaque Abeta compared with APOE3/3 BMT-recipient APPswe/PS1DeltaE9 mice.

7 e in 28/39 ablation patients (72%) and 16/36 BMT patients (44%).

8 Eight months later, APOE4/4 BMT-recipient APPswe/PS1DeltaE9 mice had significantly i

9 ell engraftment with MGMT transgenic C57BL/6 BMT after BCNU treatment, demonstrating full reconstitut

10 in 61/83 ablation patients (73.5%) and 42/84 BMT patients (50%).

11 Despite a difference in phagocytic ability, BMT AMs harbor a killing defect to both P. aeruginosa an

12 specially skin cancer, was observed in adult BMT-rescued DNA-PKcs(3A/3A) mice.

13 c allografts were performed at day 243 after BMT.

14 57BL/6 grafts was performed at day 358 after BMT.

15 -year overall survival was 95% and 97% after BMT and CBT, respectively (P = .92).

16 oid organs, and target organs of aGvHD after BMT showed significantly reduced numbers of miR-181a-tra

17 l MR examinations performed before and after BMT was collected from each patient's records.

18 also through priming of naive T cells after BMT.

19 of low levels of proliferation 4 days after BMT.

20 present on donor dendritic cells (DCs) after BMT in the setting of myeloablative conditioning but is

21 cells (DCs) is markedly impaired early after BMT.

22 NET formation after BMT was rescued both in vitro and in vivo with cyclooxyg

23 ring C57BL/6 mice did not develop GvHD after BMT even when the bone marrow inoculum was supplemented

24 when reconstructing antiviral immunity after BMT, and highlight the mechanisms by which the adoptive

25 at high risk for cognitive impairment after BMT.

26 HLI surgery was performed 1 mo after BMT, after confirming complete engraftment of the recipi

27 r origin CD8(+) cells detected 1 month after BMT, and remained stable (85.5 +/- 11% mean donor origin

28 Variants Related to one-Year mortality after BMT), a well-powered genome-wide association study consi

29 ly severe non-GVHD hepatitis occurring after BMT, determined using a proteomic approach and enabling

30 l (DFS) was 86% and 80% in TM patients after BMT and CBT, respectively, whereas DFS in SCD patients w

31 tly associated with different survival after BMT for hematologic malignancies.

32 ted mortality, and/or overall survival after BMT.

33 nsion and suppressive function of Treg after BMT.

34 ver, specific depletion of donor Tregs after BMT also induced cGVHD, whereas adoptive transfer of Tre

35 vo expansion/maturation of donor Tregs after BMT.

36 itional on surviving the first 2 years after BMT, 5-year survival generally exceeds 70%.

37 4 and 2014 and survived for >= 2 years after BMT.

38 ches in secondary lymphoid organs after allo-BMT and define a framework of early cellular and molecul

39 dministration of a VIP antagonist after allo-BMT is a promising safely therapeutic approach to enhanc

40 show that the development of GVHD after allo-BMT prevented NK-cell reconstitution, particularly withi

41 ntestinal epithelial cells (IECs) after allo-BMT resulted in decreased histone acetylation, which was

42 trol of cytomegalovirus infection after allo-BMT was also impaired during GVHD.

43 bited interferon-gamma production after allo-BMT.

44 cellular source of Notch ligands after allo-BMT.

45 umor-bearing mice given T-cell-depleted allo-BMT (allo-TCD-BMT) failed to develop GvHD and also showe

46 ly stronger GvT effects than mice given allo-BMT.

47 nfiltrating cells compared with that in allo-BMT recipients, with significantly reduced donor-derived

48 window after transplantation in a mouse allo-BMT model.

49 cal blockade of VIP-signaling protected allo-BMT recipients from lethal murine CMV (mCMV) infection,

50 f tumors because its resection prior to allo-BMT promptly resulted in development of GvHD.

51 wing allogeneic bone marrow transplant (allo-BMT) is controlled by donor-derived cellular immunity.

52 fter allogeneic bone marrow transplant (allo-BMT).

53 Allogeneic bone marrow transplantation (allo-BMT) is a curative therapy for hematological malignancie

54 allogeneic bone marrow transplantation (allo-BMT).

55 allogeneic bone marrow transplantation (allo-BMT).

56 allogeneic bone marrow transplantation (allo-BMT).

57 Allogeneic BMT and its major complication, graft-versus-host diseas

58 6% non-Hispanic whites; and 46.6% allogeneic BMT recipients).

59 MT, in the presence of GVHD after allogeneic BMT, CMV induced a striking cytopathy resulting in unive

60 ptimizing vaccine responses after allogeneic BMT.

61 of subsequent breast cancer among allogeneic BMT survivors (hazard ratio [HR], 3.7 [95% CI, 1.2 to 11

62 Five patients who received an allogeneic BMT for the treatment of hematological diseases develope

63 sease risk across histologies and allogeneic BMT regimens.

64 cantly lower incidence of GVHD in allogeneic BMT recipients.

65 sk of subsequent breast cancer in allogeneic BMT survivors and a 4.6-fold higher risk in autologous B

66 monstrate, using murine models of allogeneic BMT, that type 2 innate lymphoid cells (ILC2s) in the lo

67 Although BMT increases the life span of patients with MPS IH, mus

68 as well as in the in vivo MLL-rearranged AML BMT model coupled with treatment of "5 + 3" (i.e. DOX pl

69 uated two selective NR2B NAMs, CP101,606 and BMT-108908, along with the nonselective NMDA antagonists

70 nd 72 patients were assigned to ablation and BMT, respectively.

71 nstrated by in vitro proliferation assay and BMT.

72 analysis, DFS did not differ between CBT and BMT recipients.

73 mes after both HLA-identical sibling CBT and BMT.

74 strong predictor of outcome for both IST and BMT, and must be considered when designing therapeutic s

75 point outcome between ablation patients and BMT patients.

76 isolation was the primary ablation approach; BMT comprised rate or rhythm control.

77 Adjusting for BMT type, age at BMT, sex, race/ethnicity, and cognitive reserve, SNPs in

78 Jalpha18(-/-) BALB/c recipients of TLI/ATS + BMT restored day-6 donor Foxp3(+) nTreg proliferation an

79 After TLI/ATS + BMT, Gr-1(low)CD11c(+) MDCs and Gr-1(high)CD11c(neg) mye

80 pha18(-/-) BALB/c recipients after TLI/ATS + BMT.

81 of subsequent breast cancer among autologous BMT survivors (HR, 3.3 [95% CI, 1.0 to 9.0]; P = .05).

82 5% CI, 1.2 to 11.8]; P = .03) and autologous BMT survivors (HR, 2.6 [95% CI, 1.0 to 6.8]; P = .048).

83 ouse model, Tcm therapy following autologous BMT led to significant survival prolongation, with 30% t

84 ors and a 4.6-fold higher risk in autologous BMT survivors.

85 orldwide who received cyclophosphamide-based BMT regimens for leukemias between 1990 and 2007.

86 -based (RSP), 2) non-sputum Biomarker-based (BMT), 3) triage test followed by confirmatory test (TT),

87 teen recipients were CMV seropositive before BMT.

88 beta2ARKO BMT mice displayed 100% mortality resulting from cardiac

89 beta2ARKO BMT mice displayed severely reduced post-MI cardiac infi

90 rbidity, coupled with a long latency between BMT and the development of chronic health conditions nec

91 clinically relevant approach to perform both BMT and VCA simultaneously was evaluated.

92 elated retinal degeneration was mitigated by BMT.

93 eveloped and evaluated the radiotracer (11)C-BMT-136088 (1-(4'-(3-methyl-4-(((1(R)-(3-(11)C-methylphe

94 Results:(11)C-BMT-136088 baseline VT was 1.83 +/- 0.16 (MA1, n = 5) or

95 Specific binding of (11)C-BMT-136088 can be reliably measured to quantify LPA1 in

96 ntration leading to a 50% reduction of (11)C-BMT-136088 specific binding were 73 +/- 30 nmol/kg and 2

97 For the self-saturation study, (11)C-BMT-136088 VND and BPND were estimated to be 0.9 +/- 0.0

98 out immunosuppression, whereas non-Treg cell BMT recipients rejected delayed donor kidneys within 3 t

99 In contrast, 2 of 5 recipients of Treg cell BMT that were evaluable displayed chimerism in all linea

100 conjunction with allogeneic T-cell-depleted BMT could be of particular benefit in patients with B-ce

101 BaMn3Ti4O14.25, designated BMT-134, possesses the signature channel-like hollandite

102 ects in P. aeruginosa internalization as did BMT AMs.

103 ients included in both the NCI and DISCOVeRY-BMT cohorts.

104 cant SNPs replicated at P < .05 in DISCOVeRY-BMT.

105 y validated with patients from the DISCOVeRY-BMT cohort (validation dataset) with existing Illumina a

106 associations were performed using DISCOVeRY-BMT (Determining the Influence of Susceptibility COnveyi

107 es taken from NHP kidney recipients of donor BMT.

108 ppression was given after 1-month post-donor BMT.

109 In addition, infusion of extra Tregs during BMT results in a delayed reconstitution of T-cell compar

110 d by infusing extra Foxp3(GFP+) Tregs during BMT.

111 g a rotarod test, we demonstrated that early BMT greatly delayed the motor impairment in the mutant m

112 was confirmed in MHC-mismatched experimental BMT.

113 sting for transfusion type and baseline FACT-BMT score, the restrictive-strategy group had a higher F

114 nal end points were collected: HRQOL by FACT-BMT score at baseline and at days 7, 14, 28, 60, and 100

115 ted quality of life (HRQOL) measured by FACT-BMT score at day 100.

116 restrictive-strategy group had a higher FACT-BMT score at day 100 (difference of 1.6 points; 95% CI,

117 Cancer Therapy-Bone Marrow Transplant (FACT-BMT) score relative to baseline.

118 A total of 1,464 female BMT survivors (allogeneic: n = 788; autologous: n = 676)

119 During the year that followed BMT, all patients presented with GVHD.

120 re, we studied CAR T-cell function following BMT using an immunocompetent murine model of minor misma

121 rived MHC class I and II molecules following BMT.

122 For BMT survivors, screening recommendations must incorporat

123 ideation was rare (1.9% for DBS vs 0.9% for BMT; Fisher's exact p=0.61).

124 Adjusting for BMT type, age at BMT, sex, race/ethnicity, and cognitive

125 nsive review articles, clinicians caring for BMT recipients continue to field frequently asked questi

126 In patients otherwise fit for BMT, the results support consideration of this approach

127 r clonotype overlap relative to myeloma-free BMT recipients.

128 d NET formation in neutrophils isolated from BMT mice or HSCT patients.

129 d, with a median follow-up of 9.3 years from BMT.

130 Compared with patients given BMT, CBT recipients were significantly younger (median a

131 udy evaluated the effect of age on NMA haplo-BMT outcomes in patients age 50 to 75 years.

132 NMA haplo-BMT with post-transplantation cyclophosphamide has encou

133 ears, who received NMA, T-cell-replete haplo-BMT with high-dose post-transplantation cyclophosphamide

134 tical blood or marrow transplantation (haplo-BMT) have expanded the donor pool.

135 oietic lineages 28 days after haploidentical BMT with 69.3 +/- 14.1%, 75.6 +/- 20.2%, and 88.5 +/- 11

136 CD8(+) cells) 6 months after haploidentical BMT.

137 uCi (90)Y-DOTA-30F11, CY, and haploidentical BMT were cured and lived >200 days.

138 atifies recipients of NMA HLA-haploidentical BMT with PTCy and also suggests that this transplantatio

139 of nonmyeloablative (NMA) HLA-haploidentical BMT with PTCy, 372 consecutive adult hematologic maligna

140 RIT-mediated haploidentical BMT without TBI may increase treatment options for aggre

141 orter (-7.23 days, 95% CI: -10.64, -3.83) in BMT-exposed versus MMT-exposed neonates.

142 patients by 8.8% (95% CI, 5.8%-11.9%) and in BMT patients by 7.3% (4.3%-10.3%; P=0.36).

143 ablation patients to a similar extent as in BMT patients.

144 ave shown trends of reduced aspergillosis in BMT patients; however, no survival benefits were seen, a

145 e found increased MHC class II expression in BMT-derived microglia and decreased oxidative damage in

146 GVHD, sustain GVT, and prevent mortality in BMT.

147 re reduced (61.0% and 44.1% respectively) in BMT-recipient AD mice, which had 20.8% more retinal gang

148 nate immune function and oxidative stress in BMT recipient mice.

149 rtic atherosclerotic plaques in both Ldlr(-/-BMT: Flnao/fl/LC) and AdPCSK9-infected Flna (o/fl)/ LC m

150 mice, which have increased pregnancy losses, BMT from WT donors leads to normalized uterine expressio

151 lar survivals to those seen with HLA-matched BMT.

152 ity complex (MHC)-mismatched and MHC-matched BMT following conditioning with lethal and sublethal irr

153 ing a minor histocompatibility Ag-mismatched BMT (B6 --> B6 x C3H.SW) followed by adoptive transfer o

154 major histocompatibility complex mismatched BMT with or without Treg cell infusion.

155 LI/ATG/alkylator regimens for MHC-mismatched BMT for hemoglobinopathies.

156 Here, we describe our approach to monitoring BMT survivors for risk-based screening and early detecti

157 ched sibling (matched sibling donors [MSDs]) BMT in 66 patients.

158 e initiation phase of acute GVHD in a murine BMT model.

159 ed for its ability to prevent GVHD in murine BMT models across minor or major histocompatibility barr

160 ration was possible in an MHC-matched murine BMT model (B10.BR-->CBA) with a CBA-derived myeloid leuk

161 plex (MHC)-mismatched and MHC-matched murine BMT models, we found that Sirt-1(-/-) T cells had a redu

162 We observed that neonatal BMT was effective at restoring alpha-l-iduronidase activ

163 d Marrow Transplant Clinical Trials Network (BMT CTN) 0802, a phase 3 multicenter randomized double-b

164 d Marrow Transplant Clinical Trials Network (BMT CTN) phase 2 trial conducted from 2008 to 2014 enrol

165 st disease remain important complications of BMT.

166 ysis model and estimated summary measures of BMT versus MMT on several outcomes.

167 HD, preserve GVT, and improve the outcome of BMT.

168 mune conditioning may improve the outcome of BMT.

169 Since the first studies of BMT in the late 1980s, a number of conditioning regimens

170 e only minimally responsive if the timing of BMT delays, suggesting already irreversible bone damage.

171 Treatment of BMT or HSCT neutrophils with phorbol 12-myristate 13-ace

172 n 2 years and 98% occurred within 3 years of BMT.

173 ss are of high clinical interest to optimize BMT procedures and underscore the importance of accessor

174 tment, using the CSF-1R antagonist GW2580 or BMT from CCR2-deficient donors, reduced perineurial inva

175 Other BMT options include unrelated cord blood or mismatched f

176 26.1) in 16 thalassemia patients to perform BMT using phenotypically HLA-identical or 1-antigen-mism

177 To test this, we performed BMT in APPswe/PS1DeltaE9 double transgenic mice using gr

178 In the PGIA BMT model, after an initial predominance of host Tregs,

179 Post-BMT, T-cell counts remained significantly lower compared

180 , including T cells, for up to 335 days post-BMT.

181 5), and miR-155 expression is decreased post-BMT.

182 oped CMV viremia during the first month post-BMT.

183 same BMT donor) was performed 4 months post-BMT without immunosuppression to assess for robust donor

184 pproached pretransplant levels 3 months post-BMT.

185 ants enhanced the prediction of risk of post-BMT cognitive impairment beyond that offered by demograp

186 plus genetic) risk prediction models of post-BMT impairment.

187 ving an impaired innate immune response post-BMT.

188 Pre-BMT exposure to alkylating agents was associated with an

189 those exposed at a young age, as well as pre-BMT exposure to alkylating agents, should inform breast

190 Patients with pre-BMT chest radiation or a history of breast cancer were e

191 s must incorporate risks associated with pre-BMT therapy as well as risks related to transplant condi

192 Prenatal BMT versus MMT may improve neonatal outcomes, but bias m

193 0sSR, 90sHR), and relapse/transplantation (R/BMT).

194 II-III of the Pesaro classification received BMT (44%) compared with CBT (39%, P < .01).

195 cts were 515 neonates whose mothers received BMT and 855 neonates whose mothers received MMT and who

196 m, was achieved in the animals that received BMT without Treg cells (N = 3).

197 Patients with EC (N = 276) who received BMT were analyzed.

198 Compared to the group receiving BMT, the combined DBS group had significantly greater me

199 In comparison with patients receiving BMT (n = 259, TM; n = 130, SCD), those given CBT (n = 66

200 Renal transplantation (from the same BMT donor) was performed 4 months post-BMT without immun

201 The issues of how and when to screen BMT survivors for therapy-related complications and exac

202 s 3 thalassemia received HLA-matched sibling BMT following either the original protocol (26 patients)

203 These studies suggest that simultaneous BMT and VCA may establish indefinite allograft survival

204 Following STAT6(-/-) BMT, donor nTregs demonstrated no loss of proliferation

205 infection was self-limiting after syngeneic BMT, in the presence of GVHD after allogeneic BMT, CMV i

206 otency to those administered after syngeneic BMT.

207 elopment of autoimmune disorder in syngeneic BMTs.

208 The GvT effects in allo-TCD-BMT recipients were associated with profound changes in

209 ice given T-cell-depleted allo-BMT (allo-TCD-BMT) failed to develop GvHD and also showed significantl

210 We conclude that BMT at a very early stage in life markedly reduces signs

211 We found that BMT suppressed the reduced myelination and the increased

212 eta in experimental AD, we hypothesized that BMT would mitigate retinal neurotoxicity through decreas

213 These data offer the possibility that BMT might provide the first therapy for MLIV.

214 Together, these findings suggest that BMT-derived APOE3-expressing cells are superior to those

215 t peripheral donor cells originated from the BMT and not from the VCA.

216 reliable change from data obtained from the BMT group, the combined DBS group also displayed higher

217 Participants were drawn from the BMT Survivor Study (BMTSS), a retrospective cohort study

218 n independent nonoverlapping cohort from the BMT Survivor Study with self-report of learning/memory p

219 ins, a significantly higher rate than in the BMT group (3%).

220 age treatment plays a lesser role,(1) in the BMT population, approximately 8% of all patients (or 36%

221 tates life-long risk-based monitoring of the BMT survivors.

222 eter ablation of AF or best medical therapy (BMT).

223 rolled study comparing best medical therapy (BMT, n=116) and bilateral deep brain stimulation (DBS, n

224 itive chemoradiotherapy (bimodality therapy [BMT]) experience frequent relapses.

225 Thus, BMT is neuroprotective in age-related as well as AD-rela

226 ariatric surgery was cost saving compared to BMT (total cost GBPpound 22,057 versus GBPpound 26,286 r

227 mg, 95% CI: -7.26, 0.07) in those exposed to BMT.

228 BM transplant (BMT) from wild-type (WT) to Hoxa11-/- mice results in st

229 and those undergoing bone marrow transplant (BMT) are at greatest risk for contracting IFDs.

230 ths before and after bone marrow transplant (BMT) from his RSV-immune father.

231 d outcomes after blood or marrow transplant (BMT) have been conducted.

232 nt murine allogeneic bone marrow transplant (BMT) models.

233 reported that murine bone marrow transplant (BMT) neutrophils overexpress cyclooxygenase-2, overprodu

234 receiving allogeneic bone marrow transplant (BMT) with minimal conditioning.

235 BM transplantation (BMT) frequently requires irradiation preconditioning to

236 Furthermore, BM transplantation (BMT) from either COX-2-deficient or mPGES-1-deficient mi

237 we generated 2 chimeric BM transplantation (BMT) models where both young green fluorescent protein (

238 d at 4 time points after BM transplantation (BMT).

239 te GVHD after allogeneic BM transplantation (BMT).

240 ogous bone marrow stem cell transplantation (BMT) were evaluated.

241 tolerance after bone marrow transplantation (BMT) across major histocompatibility complex (MHC) dispa

242 rance following bone marrow transplantation (BMT) across MHC barriers via recipient invariant NKT (iN

243 betaARKO) or WT bone-marrow transplantation (BMT) and after full reconstitution underwent MI surgery.

244 wing allogeneic bone marrow transplantation (BMT) and is characterized by tissue fibrosis manifesting

245 reated with blood or marrow transplantation (BMT) and that inclusion of these SNPs improves risk pred

246 imerism through bone marrow transplantation (BMT) are currently being pursued.

247 allogeneic blood and marrow transplantation (BMT) as a curative therapy for hematological malignancie

248 g/replating and bone marrow transplantation (BMT) assays showed that Alox5 exhibited a moderate anti-

249 < .0001) after bone marrow transplantation (BMT) by inhibiting the initiation phase of acute GVHD in

250 rative and only bone marrow transplantation (BMT) can correct the underlying enzymatic defect.

251 Neonatal bone marrow transplantation (BMT) could offer a novel therapeutic opportunity for gen

252 ing a series of bone marrow transplantation (BMT) experiments in transgenic mice expressing single mu

253 Bone marrow transplantation (BMT) for class 3 patients with thalassemia is challengin

254 nical models of bone marrow transplantation (BMT) for MM using Vk*MYC myeloma-bearing recipient mice

255 acaque model of bone marrow transplantation (BMT) for tolerance induction.

256 psing following bone marrow transplantation (BMT) has a dismal prognosis.

257 Indeed, bone marrow transplantation (BMT) has its genesis in rodent models dating back to the

258 ipients of blood and marrow transplantation (BMT) have been published by 3 major societies: American

259 lowing congenic bone marrow transplantation (BMT) in a proteoglycan-induced arthritis (PGIA) mouse mo

260 Bone marrow transplantation (BMT) is the other therapeutic option: a matched sibling

261 Blood or marrow transplantation (BMT) is used with curative intent for hematologic malign

262 ficantly affect bone marrow transplantation (BMT) outcomes.

263 Bone marrow transplantation (BMT) performance can be limited by a lack of ideal donor

264 Because bone marrow transplantation (BMT) results in decreased cerebral Abeta in experimental

265 , which require bone marrow transplantation (BMT) to prevent early mortality.

266 Bone marrow transplantation (BMT) was performed from donor SCD mice to wild-type, PCS

267 Haploidentical bone marrow transplantation (BMT) with 300 muCi (90)Y-anti-CD45 RIT and CY, without T

268 loidentical blood or marrow transplantation (BMT) with high-dose posttransplantation cyclophosphamide

269 ic by combining bone marrow transplantation (BMT) with kidney transplantation following non-myeloabla

270 fter allogeneic bone marrow transplantation (BMT), particularly in the presence of graft-versus-host

271 Here we use bone marrow transplantation (BMT), total body irradiation (TBI) and abdominal irradia

272 urine models of bone marrow transplantation (BMT), we find that MHCII(-/-)-->wild-type BMT developed

273 fter allogeneic bone marrow transplantation (BMT).

274 the efficacy of bone marrow transplantation (BMT).

275 wing allogeneic bone marrow transplantation (BMT).

276 ents undergoing bone marrow transplantation (BMT).

277 s of allogeneic bone marrow transplantation (BMT).

278 r relapse after bone marrow transplantation (BMT).

279 t disease after bone marrow transplantation (BMT).

280 ution following bone marrow transplantation (BMT).

281 fter allogeneic bone marrow transplantation (BMT).

282 fects following bone marrow transplantation (BMT).

283 reported after bone marrow transplantation (BMT).

284 sirable goal in bone marrow transplantation (BMT).

285 patients after bone marrow transplantation (BMT).

286 wing allogeneic bone marrow transplantation (BMT).

287 CBT, n = 96) or bone marrow transplantation (BMT, n = 389).

288 renatal buprenorphine maintenance treatment (BMT) versus methadone maintenance treatment (MMT) may im

289 ort when compared to best medical treatment (BMT).

290 A phase 3 clinical trial (BMT CTN 0402) comparing tacrolimus/sirolimus (Tac/Sir) v

291 n (BMT), we find that MHCII(-/-)-->wild-type BMT developed disease, with defective development of inn

292 llows thalassemia patients to safely undergo BMT from RDs who are not HLA-matched siblings, with tran

293 Using BMT (with unit cost of US$2-4) would cost US$70-121 mill

294 st-effectiveness of bariatric surgery versus BMT for patients over a 5-year time horizon.

295 ts of unbiased genome-wide associations with BMT clinical outcomes given the ultimate goal of improvi

296 Fewer women treated with BMT used illicit opioids near delivery (risk ratio=0.44,

297 Interestingly, aged wt BMT recipients also had significantly more neurons (25.4

298 pared with approximately 20% mortality in WT BMT mice.

299 -MI survival rates comparable to those in WT BMT mice.

300 In adult p75KO with the WT-BMT, proliferative (Ki67(+)) cells were detected only by